EntreMed (ENMD) Said ENMD-2076 Demonstrates Antitumor Activity

June 2, 2008 7:11 AM EDT

EntreMed, Inc. (Nasdaq: ENMD) announced the presentation of preclinical data for its Aurora A/angiogenesis kinase inhibitor, ENMD-981693, the free base of ENMD-2076.

ENMD-2076 free base exhibited dose-dependent cytotoxicity towards multiple myeloma (MM) cell lines, and was shown to induce cell death in vitro following relatively short (6 hour) exposures through apoptosis via a mitochondrial pathway. Consistent with the effect of ENMD-2076 free base on several receptor tyrosine kinases, inhibition of phosphorylation of proteins in the oncogenic PI3-kinase/Akt pathway including p-BAD, p-FOXO1a, and p-GSK3beta was observed. Longer incubations of MM cells (24-48 hours) with ENMD-2076 free base elicited increased cell death with concomitant inhibition of Aurora A autophosphorylation, induction of cell cycle arrest, and downregulation of cyclins A and B1. ENMD-2076, administered either on a daily or weekly schedule, elicited complete inhibition of tumor growth towards a xenograft of the human myeloma cell line H929 in vivo.

Related Categories

FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?